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Introduction {#jdv15454-sec-0006}
============

The incidence of melanoma is rapidly increasing and resulting mortality has risen significantly over the past 30 years.[1](#jdv15454-bib-0001){ref-type="ref"} An increased incidence of invasive melanoma has been reported worldwide together with a corresponding rise in intermediate‐risk patients.[2](#jdv15454-bib-0002){ref-type="ref"}, [3](#jdv15454-bib-0003){ref-type="ref"}, [4](#jdv15454-bib-0004){ref-type="ref"} After the diagnosis of a primary melanoma, patients are enrolled in follow‐up schedules depending on their risk of relapse, but due to its increasing prevalence, the workload and costs of surveillance programs have increased markedly.[5](#jdv15454-bib-0005){ref-type="ref"}, [6](#jdv15454-bib-0006){ref-type="ref"}, [7](#jdv15454-bib-0007){ref-type="ref"}, [8](#jdv15454-bib-0008){ref-type="ref"} Many surveillance strategies have been proposed, mainly based on initial AJCC clinical--pathological staging;[9](#jdv15454-bib-0009){ref-type="ref"}, [10](#jdv15454-bib-0010){ref-type="ref"}, [11](#jdv15454-bib-0011){ref-type="ref"} nevertheless, there are still many 'low‐risk' melanoma patients who suffer relapses, resulting in high mortality.[9](#jdv15454-bib-0009){ref-type="ref"} In addition, approximately two thirds of patients whose melanoma will metastasize leading to death were initially sentinel lymph node biopsy (SLNB) negative (American Joint Committee on Cancer \[AJCC\] stages I and II).[12](#jdv15454-bib-0012){ref-type="ref"}, [13](#jdv15454-bib-0013){ref-type="ref"}

Due to this problem, many biomarkers have been developed to improve the identification of patients who will relapse, but with no real clinical impact until now.[14](#jdv15454-bib-0014){ref-type="ref"} Recently, new prognostic tests based on genetic profiling signatures have been developed to better identify those patients who are at a higher risk of developing metastasis leading to death.[15](#jdv15454-bib-0015){ref-type="ref"}, [16](#jdv15454-bib-0016){ref-type="ref"}, [17](#jdv15454-bib-0017){ref-type="ref"}, [18](#jdv15454-bib-0018){ref-type="ref"}, [19](#jdv15454-bib-0019){ref-type="ref"}, [20](#jdv15454-bib-0020){ref-type="ref"} A gene expression profile (GEP) test (DecisionDx‐Melanoma, Castle Biosciences, Inc., Friendswood, TX, USA) evaluates 31 genes of primary cutaneous melanoma tumours and based on the expression of these genes (genetic signature) it classifies patients into two groups of risk of relapse, low (class 1) or high (class 2). This test has been validated in several historical cohorts showing that its prognostic ability is independent from the clinical and pathological features of the tumour.[15](#jdv15454-bib-0015){ref-type="ref"}, [16](#jdv15454-bib-0016){ref-type="ref"}, [17](#jdv15454-bib-0017){ref-type="ref"}, [18](#jdv15454-bib-0018){ref-type="ref"}, [19](#jdv15454-bib-0019){ref-type="ref"}, [20](#jdv15454-bib-0020){ref-type="ref"}, [21](#jdv15454-bib-0021){ref-type="ref"}, [22](#jdv15454-bib-0022){ref-type="ref"}, [23](#jdv15454-bib-0023){ref-type="ref"}, [24](#jdv15454-bib-0024){ref-type="ref"} However, this test has never before been evaluated in a prospective multicentre cohort.

Here we present a multicentre prospectively evaluated cohort of 86 patients where a 31‐gene expression profile (GEP) test was used to assess their risk of relapse.

Material and methods {#jdv15454-sec-0007}
====================

Study design {#jdv15454-sec-0008}
------------

We conducted a prospective multicentre cohort study with patients from five tertiary melanoma referral centres in Spain included between April 2015 and December 2016, who were followed up until December 2018. Patients with resected pathologic American Committee on Cancer (AJCC, 7th edition, 2009) stages IB and II primary cutaneous melanoma were invited to participate in the study (Fig. [1](#jdv15454-fig-0001){ref-type="fig"}). Furthermore, exclusion criteria included no evidence of disease within 3 months of primary surgery.

![Flow chart of the cohort.](JDV-33-857-g001){#jdv15454-fig-0001}

Patients were treated with conventional surgery followed by wide excision depending on Breslow thickness of the tumour. Patients with tumours T1b and above were staged with sentinel lymph node biopsy (SLNB) following each institution protocol. For the purpose of this study, patients with positive SLNB were excluded. The study was approved by the ethics committees of all Hospitals.

In all patients, tumour specimens were obtained from the hospital biobank. The formalin‐fixed paraffin‐embedded primary cutaneous melanoma tissue was analysed with the 31‐GEP test (DecisionDx‐Melanoma, Castle Biosciences, Inc).[15](#jdv15454-bib-0015){ref-type="ref"}, [25](#jdv15454-bib-0025){ref-type="ref"} Moreover, the RT‐PCR‐based test classifies patients into a low‐risk (Class 1) or high‐risk (Class 2) category for recurrence, as previously reported and validated.[15](#jdv15454-bib-0015){ref-type="ref"}

Disease‐free survival (DFS) was defined as the period of time in months from the date of diagnosis to the date of relapse. Patients that were free of disease at the time of the last follow‐up or died during the study period, by any other causes, were treated as censored cases for evaluation purposes. All patients were followed up prospectively according to each institution protocol to identify relapses.

According to marked differences in 5‐year survival curves for AJCC stages IIA and IIB patients (AJCC 79% vs. 68% respectively), all included subjects were further classified into two risk groups. Patients with AJCC stages IB and IIA were considered as low‐risk and IIB and IIC as high‐risk.[18](#jdv15454-bib-0018){ref-type="ref"}, [26](#jdv15454-bib-0026){ref-type="ref"}

For better reporting of the evaluation conducted, the REMARK checklist recommendations have been applied.

Statistical analysis {#jdv15454-sec-0009}
--------------------

Pearson\'s chi‐squared and Student\'s t‐tests were used to compare categorical and continuous variables, respectively. Mann--Whitney--Wilcoxon was used to compare samples not distributed normally. Primary survival end‐points (disease‐free survival) were evaluated using Kaplan--Meier curves and univariate and multivariate Cox regression analyses. Due to the substantial censoring of survival times and several highly predictive covariates, we applied Firth\'s Correction to our Cox regression model.[27](#jdv15454-bib-0027){ref-type="ref"} The starting point for all cases was the diagnosis of primary melanoma. *P*‐values \<0.05 were considered significant. Statistical analyses were performed using SPSS v.25.0 (IBM Corp., Armonk, NY, USA), and Cox regression analysis was performed using R studio (R Studio Team (2015). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA, USA).

Results {#jdv15454-sec-0010}
=======

After applying the inclusion/exclusion criteria, 88 patients were included in the study, but two were later excluded because of a technical failure in the test. Of the remaining 86 patients, 40 patients (46.5%) were male and 46 female (53.5%), with a median age at diagnosis of 59.2 years (interquartile range \[IQR\] 47--72). Characteristics of this cohort are summarized in Table [1](#jdv15454-tbl-0001){ref-type="table"}. Patients were followed up for 2206 person‐months, with a metastasis incidence rate of 3.17 cases per 1000 person‐months. Overall median follow‐up time was 26 months (IQR 22--30).

###### 

Basal clinicopathological characteristics of the cohort and relapse data

                                Overall         Class 1 Low risk   Class 2 High risk   *P* value
  ----------------------------- --------------- ------------------ ------------------- -------------
  *n*                           86              53                 33                  --
  Follow‐up time median (IQR)   26 (22--30)     27 (23--32)        24 (20--29)         0.066
  Sex                                                                                  
  Male                          40 (46.5%)      21 (40%)           19 (58%)            0.105
  Female                        46 (53.5%)      32 (60%)           14 (42%)            
  Age                                                                                  
  Median (IQR)                  59.2 (47--72)   57 (46--68)        68 (55--74)         **0.025**
  Localization                                                                         
  Acral                         5 (6%)          2 (4%)             3 (9%)              0.738
  Head and neck                 11 (13%)        7 (13%)            4 (12%)             
  Legs                          21 (24%)        15 (28%)           6 (18%)             
  Arms                          12 (14%)        7 (13%)            5 (15%)             
  Trunk                         37 (43%)        22 (41%)           15 (45%)            
  Breslow                                                                              
  Mean (SD)                     2.5 (2.3)       1.7 (1.4)          3.7 (2.9)           **\<0.001**
  ≤1.00 mm                      18 (21%)        17 (32%)           1 (3%)              **\<0.001**
  1.00--2.00 mm                 33 (38%)        23 (43%)           10 (30%)            
  2.01--4.00 mm                 22 (26%)        10 (19%)           12 (36%)            
  \>4.00 mm                     13 (15%)        3 (6%)             10 (30%)            
  Mitotic rate (mm^2^)                                                                 
  \<1 mm^2^                     9 (11%)         6 (11%)            3 (9%)              0.684
  ≥1 mm^2^                      76 (88%)        46 (87%)           30 (91%)            
  N.A.                          1 (1%)          1 (2%)             0                   
  Ulceration                                                                           
  Absent                        60 (70%)        51 (96%)           9 (27%)             **\<0.001**
  Present                       26 (30%)        2 (4%)             24 (73%)            
  AJCC stage                                                                           
  Low‐risk (IB‐IIA)             62 (72%)        48 (91%)           14 (42%             **\<0.001**
  High‐risk (IIB‐IIC)           24 (28%)        5 (9%)             19 (58%)            
  Relapse                                                                              
  No                            79 (91%)        53 (100%)          26 (79%)            **\<0.001**
  Yes                           7 (9%)          0                  7 (21%)             
  Relapse site (*n *= 7)                                                               
  Skin                          --              0                  2 (29%)             --
  Lymph node                    --              0                  2 (29%)             
  Visceral                      --              0                  3 (43%)             

AJCC, American Joint Committee on Cancer; IQR, Interquartile range; N.A., Not Available; SD, Standard Deviation.

*P*‐values are bold where they are less than or equal to the significance level cut‐off of 0.05.
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Class 1 and Class 2 patients showed a mean Breslow of 1.7 mm (standard deviation \[SD\] 1.4) and 3.7 mm (SD 2.9), respectively, which was statistically significant (*P \< *0.001). Moreover, Class 2 melanomas were ulcerated more often and presented significantly higher AJCC staging (Table [1](#jdv15454-tbl-0001){ref-type="table"}).

Relapses were identified in seven patients (8.1%), all corresponding to Class 2 (high‐risk) by the GEP test (*P *\< 0.001). Furthermore, the GEP risk score identified 19 patients (22.1%) with a risk score different from that predicted by AJCC classification. Five (5.8%) patients with high‐risk AJCC stage were rated as Class 1 (low risk), and 14 subjects (16.3%) with low‐risk AJCC stage were identified as Class 2 (high risk) by the GEP test. Five patients (5.8%) presented relapses with a high‐risk GEP test score and AJCC high‐risk at the same time, while two subjects (2.3%) patient were identified as Class 2 (high‐risk) by the GEP test although belonging to AJCC low‐risk.

Kaplan--Meier survival curves were analysed to evaluate DFS for the two 31‐GEP risk classes and showed statistically significant differences between the two groups (log rank *P \< *0.001). When combining the GEP test with the AJCC (log rank *P = *0.001) the significance was maintained (Fig. [2](#jdv15454-fig-0002){ref-type="fig"}).

![Kaplan--Meier estimates of disease‐free survival. (a) Kaplan--Meier curve showing disease‐free survival for the two GEP cohorts. (b) displays four subgroups of patients according to the outcomes predicted by the AJCC staging system in combination with gene GEP testing. Survival table is shown at the bottom of each figure. AJCC, American Joint Committee on Cancer.](JDV-33-857-g002){#jdv15454-fig-0002}

Following curve comparison by Kaplan--Meier method, we compared the prognostic accuracy of the GEP test to the AJCC and age using Cox regression analysis. Both univariate and multivariate analysis showed the GEP test to be an independent predictor of metastasis. Hazard ratios for the GEP test were 28.37 (95% CI 3.46--3682.91; *P *\<* *0.01) for the univariable analysis and 18.82 (95% CI 1.81--2549.76; *P *=* *0.01) for the multivariable analysis (Table [2](#jdv15454-tbl-0002){ref-type="table"}).

###### 

Univariable and multivariate Cox regression analysis of prognostic factors in 86 melanoma patients for relapse free survival

  Factor (high‐risk variable)   Univariate              Multivariate                            
  ----------------------------- ----------------------- -------------- ------------------------ ------
  GEP (Class 2)                 28.37 (3.46--3682.91)   \<0.01         18.82 (1.81--2,549.76)   0.01
  AJCC risk group (IIB‐IIC)     6.33 (1.52--35.28)      0.01           1.52 (0.36--8.77)        0.58
  Age of onset (\>50)           7.26 (0.88--942.67)     0.07           3.7 (0.43--486.05)       0.29

AJCC, American Joint Committee on Cancer; CI, Confidence interval; GEP, gene expression profile.
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Discussion {#jdv15454-sec-0011}
==========

This paper describes the results of a 31‐GEP test performed to better categorize patients with low to intermediate‐risk melanoma according to the AJCC staging system. We present the data from a multicentre cohort study in which patients with malignant melanoma were followed up prospectively after the 31‐GEP test. We observed that seven patients (8.1%) presented relapses within a median of 12 months (IQR 5--21), all seven belonging to the Class 2 group (overall, 21.2% of the Class 2 group). Kaplan--Meier survival curves were statistically different between both groups with an increased risk of recurrence in the Class 2 group with a hazard ratio of 28.37 and 18.82, for univariate and multivariate Cox regression analysis, respectively. Similarly, a previous validation study of the 31‐GEP test showed that the metastatic risk was predicted with high accuracy in the Class 2 cohort of primary cutaneous melanomas, with a receiver operating characteristic (ROC) curve value of 0.91--0.93.[15](#jdv15454-bib-0015){ref-type="ref"}

Subsequent studies have analysed the use of the 31‐GEP test in combination with the AJCC stage system and found that this approach improves the identification of patients at risk of relapse.[18](#jdv15454-bib-0018){ref-type="ref"}, [19](#jdv15454-bib-0019){ref-type="ref"} In this report, we also combined GEP with the AJCC score confirming that patients with higher AJCC (IIB‐IIC) staging and Class 2 GEP are at a greater risk of relapse. Nevertheless, two patients with a low‐risk AJCC stage and a Class 2 GEP metastasized. Based solely on AJCC staging, many patients classified at low‐risk will relapse as seen in the study by Ferris *et al*. where 43% of the cases classified as Class 2 GEP and AJCC low risk, relapsed. This has a profound impact on high‐risk patients based on the GEP test, but at lower AJCC stages who could opt for intensive follow‐up,[9](#jdv15454-bib-0009){ref-type="ref"} but are at early stages of the AJCC. Moreover in the new era of adjuvant therapies, patients at greater risk of relapse could be selected for these treatment schemes and improve overall survival.

Moreover, GEP tests have been used in combination with SLNB status resulting in different outcomes of disease‐free survival, distant metastasis free survival, and overall survival curves.[16](#jdv15454-bib-0016){ref-type="ref"} The authors have observed that patients with negative SLNB and class 2 GEP have a worse prognosis than patients with positive SLNB and class 1 GEP status.[16](#jdv15454-bib-0016){ref-type="ref"}, [21](#jdv15454-bib-0021){ref-type="ref"} In the present study, we only included SLN negative patients, to evaluate the performance of this test in identifying those at a high risk of melanoma relapsing during early stages. It may be that the use of genetic signatures in conjunction with the classic clinical, pathological criteria of AJCC and the SLNB status will significantly improve the detection of patients at risk of relapse. Accordingly, we believe that validating a gene assay test will be an important step towards the goal of optimizing follow‐up protocols and we propose personalized adjuvant therapy in low to intermediate‐risk melanoma patients.

As a limitation of this study, we observed that patients who tested as Class 2 GEP had a tendency towards thicker melanomas, higher frequency of ulceration and higher AJCC stages. However, univariate and multivariate Cox regression analyses showed that the GEP test was an independent prognostic factor. Moreover, we had a low incidence of events, so the external validity should be interpreted with caution. This could be explained by the follow‐up time being relatively short, although most of the metastases developed within the first two years of follow‐up. The number of relapses is then, in accordance with that published in the literature.[8](#jdv15454-bib-0008){ref-type="ref"}, [13](#jdv15454-bib-0013){ref-type="ref"} Moreover, due to the multicentre and prospective design of this study and the assessment of this test in 'real daily practice', the GEP test gives useful information about what to expect during the first two years of follow‐up, as we observed that 21% of the patients in the class 2 group developed metastasis.

Conclusion {#jdv15454-sec-0012}
==========

We observed that a 31‐GEP test allows the accurate prediction of patients at a high risk of relapse, despite having a low‐risk AJCC staging. We believe that GEP in combination with AJCC staging system could well improve the detection of patients who need intensive surveillance and optimize follow‐up strategies.
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